箭头制药

ARWR NASDAQ
28.16
+0.36
+1.30%
盘后: 28.26 +0.1 +0.36% 19:59 07/16 EDT
开盘
27.81
昨收
27.80
最高
28.33
最低
27.60
成交量
73.75万
成交均量(3M)
205.13万
52周最高
28.84
52周最低
10.41
换手率
0.78%
市值
26.70亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供箭头制药 ARWR股票价格,箭头制药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.
展开 >

最近浏览

名称
价格
涨跌幅